Acurx Pharmaceuticals (ACXP) Competitors $4.17 0.00 (0.00%) Closing price 09/16/2025 04:00 PM EasternExtended Trading$4.20 +0.03 (+0.60%) As of 09/16/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ACXP vs. CVKD, AKTX, ENLV, RLYB, CLSD, GDTC, XCUR, NEUP, ALLR, and QTTBShould you be buying Acurx Pharmaceuticals stock or one of its competitors? The main competitors of Acurx Pharmaceuticals include Cadrenal Therapeutics (CVKD), Akari Therapeutics (AKTX), Enlivex Therapeutics (ENLV), Rallybio (RLYB), Clearside Biomedical (CLSD), CytoMed Therapeutics (GDTC), Exicure (XCUR), Neuphoria Therapeutics (NEUP), Allarity Therapeutics (ALLR), and Q32 Bio (QTTB). These companies are all part of the "pharmaceutical products" industry. Acurx Pharmaceuticals vs. Its Competitors Cadrenal Therapeutics Akari Therapeutics Enlivex Therapeutics Rallybio Clearside Biomedical CytoMed Therapeutics Exicure Neuphoria Therapeutics Allarity Therapeutics Q32 Bio Acurx Pharmaceuticals (NASDAQ:ACXP) and Cadrenal Therapeutics (NASDAQ:CVKD) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, analyst recommendations, valuation, earnings, risk, institutional ownership, profitability and media sentiment. Which has better valuation and earnings, ACXP or CVKD? Cadrenal Therapeutics is trading at a lower price-to-earnings ratio than Acurx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAcurx PharmaceuticalsN/AN/A-$14.10M-$10.69-0.39Cadrenal TherapeuticsN/AN/A-$10.65M-$8.88-1.50 Is ACXP or CVKD more profitable? Cadrenal Therapeutics' return on equity of -265.37% beat Acurx Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Acurx PharmaceuticalsN/A -436.83% -192.25% Cadrenal Therapeutics N/A -265.37%-196.38% Do analysts recommend ACXP or CVKD? Acurx Pharmaceuticals presently has a consensus price target of $31.00, indicating a potential upside of 643.41%. Cadrenal Therapeutics has a consensus price target of $32.00, indicating a potential upside of 139.70%. Given Acurx Pharmaceuticals' higher possible upside, equities analysts plainly believe Acurx Pharmaceuticals is more favorable than Cadrenal Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Acurx Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Cadrenal Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders and institutionals believe in ACXP or CVKD? 11.5% of Acurx Pharmaceuticals shares are owned by institutional investors. Comparatively, 7.9% of Cadrenal Therapeutics shares are owned by institutional investors. 20.3% of Acurx Pharmaceuticals shares are owned by company insiders. Comparatively, 26.1% of Cadrenal Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Does the media refer more to ACXP or CVKD? In the previous week, Cadrenal Therapeutics had 5 more articles in the media than Acurx Pharmaceuticals. MarketBeat recorded 7 mentions for Cadrenal Therapeutics and 2 mentions for Acurx Pharmaceuticals. Acurx Pharmaceuticals' average media sentiment score of 0.95 beat Cadrenal Therapeutics' score of 0.66 indicating that Acurx Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Acurx Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cadrenal Therapeutics 0 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility & risk, ACXP or CVKD? Acurx Pharmaceuticals has a beta of -1.29, suggesting that its stock price is 229% less volatile than the S&P 500. Comparatively, Cadrenal Therapeutics has a beta of 0.95, suggesting that its stock price is 5% less volatile than the S&P 500. SummaryCadrenal Therapeutics beats Acurx Pharmaceuticals on 6 of the 11 factors compared between the two stocks. Get Acurx Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ACXP and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ACXP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ACXP vs. The Competition Export to ExcelMetricAcurx PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.61M$3.12B$5.73B$10.31BDividend YieldN/A2.36%5.90%4.63%P/E Ratio-0.3921.1676.0226.51Price / SalesN/A446.35533.19123.58Price / CashN/A45.4037.1760.46Price / Book6.629.6213.806.29Net Income-$14.10M-$53.28M$3.28B$270.51M7 Day Performance2.46%1.01%0.82%1.95%1 Month Performance-18.40%4.58%4.62%6.33%1 Year Performance-89.68%8.35%82.65%25.62% Acurx Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ACXPAcurx Pharmaceuticals2.2292 of 5 stars$4.17flat$31.00+643.4%-89.7%$6.61MN/A-0.393CVKDCadrenal Therapeutics3.2778 of 5 stars$13.36+1.6%$32.00+139.5%+20.0%$26.92MN/A-1.504Short Interest ↓High Trading VolumeAKTXAkari Therapeutics3.7163 of 5 stars$0.78-1.7%$3.30+325.5%-76.9%$25.73MN/A0.009ENLVEnlivex Therapeutics2.5372 of 5 stars$1.07-0.5%$10.00+839.0%-29.9%$25.31MN/A-1.8470RLYBRallybio3.2662 of 5 stars$0.59-1.2%$5.00+742.6%-45.5%$25.10M$640K-0.6340Positive NewsShort Interest ↓CLSDClearside Biomedical2.3621 of 5 stars$3.95-17.6%$63.00+1,494.9%-81.8%$25.08M$4.17M-10.6830Stock SplitGDTCCytoMed Therapeutics2.453 of 5 stars$2.13-6.4%$5.00+135.3%+33.4%$24.83M$69.50K0.00N/APositive NewsXCURExicure1.444 of 5 stars$4.07+4.9%N/A+77.0%$24.48M$500K-1.0550Positive NewsNEUPNeuphoria Therapeutics2.5884 of 5 stars$12.07-7.2%$28.00+132.0%N/A$24.46M$10K0.00N/AALLRAllarity Therapeutics2.1175 of 5 stars$1.63-1.8%$9.00+452.1%-55.0%$24.27MN/A0.0010Gap DownQTTBQ32 Bio2.7513 of 5 stars$1.81-6.2%$12.17+572.2%-95.8%$23.54M$1.16M-0.4239Gap Down Related Companies and Tools Related Companies Cadrenal Therapeutics Alternatives Akari Therapeutics Alternatives Enlivex Therapeutics Alternatives Rallybio Alternatives Clearside Biomedical Alternatives CytoMed Therapeutics Alternatives Exicure Alternatives Neuphoria Therapeutics Alternatives Allarity Therapeutics Alternatives Q32 Bio Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ACXP) was last updated on 9/17/2025 by MarketBeat.com Staff From Our PartnersHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acurx Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Acurx Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ACXP Stock Alerts